Clinical Performance of Bioglass-Enriched Resin Modified Glass Ionomer in Sealing Moderate Carious Lesions: An 18-Month Split-Mouth Clinical Trial.

UNLABELLED: Dental materials with the potential for caries progression prevention have been an attractive alternative to minimally invasive treatments.

OBJECTIVES

This randomized controlled split-mouth clinical trial aimed to assess, after 18 months, the retention, restoration quality, and caries progression or arrestment of active moderate carious lesions (International Caries Detection and Assessment System [ICDAS] 3-4) sealed with resin-modified glass ionomer cement (RMGIC) and 45S5 bioglass-enriched RMGIC (RMGIC/45S5).

METHODOLOGY: A total of 52 molars with occlusal caries (ICDAS 3-4) were selected. For this split-mouth clinical trial, the permanent molars without mechanical preparation were randomly sealed with RMGIC or RMGIC/45S5. After 18 months, the restorations were compared with the initial treatment (baseline) regarding retention, quality of the remaining material (anatomical shape, marginal adaptation, surface texture, and marginal discoloration), and clinical/radiographic caries progression. The Wilcoxon and Fisher's exact tests were used for data evaluation.

RESULTS

After 18 months, no statistically significant differences were found in the retention and material quality of teeth treated with RMGIC or RMGIC/45S5 (p > 0.05). The clinical and radiographic evaluations showed no statistical difference between the materials when considering caries arrestment and progression (p > 0.05).

CONCLUSIONS

The addition of 45S5 bioglass to RMGIC did not change the retention, restoration quality, and caries progression or arrestment levels after 18 months of follow-up.